Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1) acute myeloid leukemia (AML)

By sjmartinez • March 28, 2024

Cortes J, Jonas BA, Schiller G, Mims A, Roboz GJ, Wei AH, Montesinos P, Ferrell PB, Yee KW, Fenaux P, Schwarer A, Watts JM. Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML). Leuk Lymphoma. 2024 Mar 27:1-8. doi: 10.1080/10428194.2024.2333451. Epub ahead of print. PMID: 38538632.

Tags: Acute myeloid leukemia, Hematology/Oncology, IDH1 mutation, Olutasidenib, Publications

Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

Rodriguez GE, Zhao Y, Nishiga Y, Peprah F, Shen J, Abhiraman GC, Ogishi M, Zhang C, Saco J, Waghray D, Serasanambati M, Torres L, Simone[...]

Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases

Ni JR, Quirk M, Chmielowski B, Padia SA. Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases. Cardiovasc Intervent Radiol.[...]

Advancements in intratumoral therapies for liver tumors

Raman SS, Cutler NR, Sramek JJ, Hecht JR, Finn RS, Anand SR, Chiang J, Lu DS. Advancements in intratumoral therapies for liver tumors. Front Oncol.[...]